Scholarlink

<p>Biliary tract cancer, also known as cholangiocarcinoma (CCA), is a&#xa0;heterogeneous group of tumors that include carcinomas of the intrahepatic, perihilar, extrahepatic (distal) bile ducts and the gallbladder. Accounting for less than 2% of all malignant tumors, they are considered rare cancers; however, both the incidence and mortality rates of CCA have been rising worldwide over the past decades. The prognosis remains poor with a&#xa0;5-year survival rate of only 7–20%. In localized stages complete surgical resection is the preferred treatment option. Nevertheless, the 5‑year survival rate even after curative surgery is only 50%. For inoperable tumors, contraindications to surgery or in metastatic/relapsed stages, systemic therapy is the primary treatment strategy. In such cases, comprehensive molecular diagnostics are essential as CCAs are a&#xa0;prime example of the use of targeted substances, which have substantially expanded the palliative therapy landscape.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Therapie der Cholangiokarzinome

  • 期刊论文

  • 发表日期：

    2025年8月15日

查看全文
  • Ilektra Antonia Mavroeidi,
  • Stefan Kasper,
  • Vivian Rosery

摘要

Biliary tract cancer, also known as cholangiocarcinoma (CCA), is a heterogeneous group of tumors that include carcinomas of the intrahepatic, perihilar, extrahepatic (distal) bile ducts and the gallbladder. Accounting for less than 2% of all malignant tumors, they are considered rare cancers; however, both the incidence and mortality rates of CCA have been rising worldwide over the past decades. The prognosis remains poor with a 5-year survival rate of only 7–20%. In localized stages complete surgical resection is the preferred treatment option. Nevertheless, the 5‑year survival rate even after curative surgery is only 50%. For inoperable tumors, contraindications to surgery or in metastatic/relapsed stages, systemic therapy is the primary treatment strategy. In such cases, comprehensive molecular diagnostics are essential as CCAs are a prime example of the use of targeted substances, which have substantially expanded the palliative therapy landscape.